Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1998 1
2001 1
2006 1
2008 1
2009 2
2010 3
2011 3
2014 2
2016 4
2017 2
2018 1
2019 1
2020 1
2021 3
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Rufinamide add-on therapy for drug-resistant epilepsy.
Panebianco M, Prabhakar H, Marson AG. Panebianco M, et al. Cochrane Database Syst Rev. 2020 Nov 8;11(11):CD011772. doi: 10.1002/14651858.CD011772.pub3. Cochrane Database Syst Rev. 2020. PMID: 33179247 Free PMC article.
However, the trials reviewed were of relatively short duration and provided no evidence for long-term use of rufinamide. In the short term, rufinamide as an add-on was associated with several adverse events. ...Likewise, no inference can be made about the effects of …
However, the trials reviewed were of relatively short duration and provided no evidence for long-term use of rufinamide. In the short …
Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan.
Ohtsuka Y, Yoshinaga H, Shirasaka Y, Takayama R, Takano H, Iyoda K. Ohtsuka Y, et al. Epilepsy Res. 2014 Nov;108(9):1627-36. doi: 10.1016/j.eplepsyres.2014.08.019. Epub 2014 Sep 2. Epilepsy Res. 2014. PMID: 25219353 Free article. Clinical Trial.
Subgroup analyses indicated that the efficacy of rufinamide was consistent independent of clinical background characteristics. ...The mean plasma concentration of rufinamide between 1 and 9 within 12h after administration was 17.2 mug/mL. ...
Subgroup analyses indicated that the efficacy of rufinamide was consistent independent of clinical background characteristics. ...The …
Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.
Sharawat IK, Panda PK, Panda P, Dawman L. Sharawat IK, et al. Seizure. 2021 Oct;91:296-307. doi: 10.1016/j.seizure.2021.07.004. Epub 2021 Jul 9. Seizure. 2021. PMID: 34273668 Free article.
INTRODUCTION: Rufinamide is an antiseizure medication that acts through sodium channels and is found to be efficacious in patients with Lennox Gastaut syndrome (LGS). However, no systematic review has been conducted in LGS patients to provide an estimate of the efficacy an …
INTRODUCTION: Rufinamide is an antiseizure medication that acts through sodium channels and is found to be efficacious in patients wi …
Rufinamide: a double-blind, placebo-controlled proof of principle trial in patients with epilepsy.
Pålhagen S, Canger R, Henriksen O, van Parys JA, Rivière ME, Karolchyk MA. Pålhagen S, et al. Epilepsy Res. 2001 Feb;43(2):115-24. doi: 10.1016/s0920-1211(00)00185-6. Epilepsy Res. 2001. PMID: 11164700 Clinical Trial.
OBJECTIVE: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy in epileptic patients. The pharmacokinetic (PK) profile of rufinamide was also determined. ...No autoinduction of rufinamide …
OBJECTIVE: This was the first proof of principle clinical trial assessing the efficacy and safety of rufinamide as adjunctive therapy …
Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome.
Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Glauser T, et al. Neurology. 2008 May 20;70(21):1950-8. doi: 10.1212/01.wnl.0000303813.95800.0d. Epub 2008 Apr 9. Neurology. 2008. PMID: 18401024 Clinical Trial.
The common adverse events (reported by >or=10% of patients receiving rufinamide) were somnolence (24.3% with rufinamide vs 12.5% with placebo) and vomiting (21.6% vs 6.3%). CONCLUSIONS: Rufinamide was an effective and well-tolerated treatment for seizures …
The common adverse events (reported by >or=10% of patients receiving rufinamide) were somnolence (24.3% with rufinamide vs …
Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: a randomized placebo-controlled trial.
Brodie MJ, Rosenfeld WE, Vazquez B, Sachdeo R, Perdomo C, Mann A, Arroyo S. Brodie MJ, et al. Epilepsia. 2009 Aug;50(8):1899-909. doi: 10.1111/j.1528-1167.2009.02160.x. Epub 2009 Jun 1. Epilepsia. 2009. PMID: 19490053 Free article. Clinical Trial.
METHODS: This double-blind, placebo-controlled, randomized, parallel-group, multicenter trial included an 8-week baseline phase and a 13-week double-blind phase. Treatment was initiated with rufinamide 400 mg twice daily or placebo; rufinamide was titrated to 1600 m …
METHODS: This double-blind, placebo-controlled, randomized, parallel-group, multicenter trial included an 8-week baseline phase and a 13-wee …
Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study.
Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Kluger G, et al. Acta Neurol Scand. 2010 Sep;122(3):202-8. doi: 10.1111/j.1600-0404.2010.01334.x. Epub 2010 Mar 1. Acta Neurol Scand. 2010. PMID: 20199521 Clinical Trial.
OBJECTIVE: This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut syndrome (LGS) who had previously completed a 12-week double-blind study. ...The most common AEs were vomiting (30.6%) and pyrexia (25.8%). …
OBJECTIVE: This open-label extension evaluated the long-term efficacy and tolerability of rufinamide in patients with Lennox-Gastaut …
Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study.
Arzimanoglou A, Ferreira JA, Satlin A, Mendes S, Williams B, Critchley D, Schuck E, Hussein Z, Kumar D, Dhadda S, Bibbiani F. Arzimanoglou A, et al. Eur J Paediatr Neurol. 2016 May;20(3):393-402. doi: 10.1016/j.ejpn.2015.12.015. Epub 2016 Jan 11. Eur J Paediatr Neurol. 2016. PMID: 26805435 Free article. Clinical Trial.

No adjustments to body weight-based rufinamide dosing in subjects 1 to < 4 years are necessary. SIGNIFICANCE: Rufinamide was safe and well tolerated in these pediatric subjects. Results from the interim analysis demonstrate that rufinamide's safety and PK

…

No adjustments to body weight-based rufinamide dosing in subjects 1 to < 4 years are necessary. SIGNIFICANCE: Rufinamide wa

…
The efficacy and safety of rufinamide in drug-resistant epilepsy: A meta-analysis of double-blind, randomized, placebo controlled trials.
Xu Z, Zhao H, Chen Z. Xu Z, et al. Epilepsy Res. 2016 Feb;120:104-10. doi: 10.1016/j.eplepsyres.2016.01.001. Epub 2016 Jan 7. Epilepsy Res. 2016. PMID: 26811934
However, rufinamide may induce more tolerable (but not severe) adverse events. Further large clinical trials to investigate the long-term efficacy and safety of rufinamide are warranted....
However, rufinamide may induce more tolerable (but not severe) adverse events. Further large clinical trials to investigate the long- …
Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis.
Verrotti A, Loiacono G, Ballone E, Mattei PA, Chiarelli F, Curatolo P. Verrotti A, et al. Pediatr Neurol. 2011 May;44(5):347-9. doi: 10.1016/j.pediatrneurol.2010.12.005. Pediatr Neurol. 2011. PMID: 21481742 Clinical Trial.
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. ...Data from 918 patients were studied. The number of patients per study varied from 25 t …
Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and dro …
27 results

Searches related to "rufinamide"